A bone marrow transplant replaces damaged or destroyed blood-forming cells with healthy stem cells, delivered through an IV line much like a blood transfusion. The infusion itself takes only 1 to 5 hours, but the full process spans weeks to months, starting with medical evaluations, moving through intensive chemotherapy or radiation to prepare the body, and ending with a lengthy recovery period while the new cells take hold.
Where the Stem Cells Come From
There are three sources of stem cells used in transplants, and the source affects how they’re collected. The original technique, introduced in the 1970s, involves extracting marrow directly from a donor’s pelvic bone using a needle while the donor is under anesthesia. Since the early 1990s, a simpler method has largely replaced this approach in adults: collecting stem cells from the donor’s bloodstream after giving them a hormone (G-CSF) that pushes stem cells out of the bone marrow and into circulating blood. The third and least common source is umbilical cord blood, collected from a newborn’s placenta and umbilical cord after delivery.
Peripheral blood collection has become the dominant method because it leads to faster recovery of blood cell counts after transplant. Survival rates are similar between peripheral blood and bone marrow sources. However, bone marrow harvesting carries a meaningful advantage: lower rates of chronic graft-versus-host disease, a long-term complication where donor cells attack the recipient’s body. Patients who receive bone marrow rather than peripheral blood stem cells also report higher quality of life five years after transplant.
Autologous vs. Allogeneic Transplants
In an autologous transplant, your own stem cells are collected before treatment, stored, and then returned to you after high-dose chemotherapy. This avoids the risk of immune rejection entirely but is only an option when your own marrow is healthy enough to harvest.
An allogeneic transplant uses cells from a donor. This requires careful matching of proteins called HLA markers on your DNA. Doctors look at up to 12 different HLA markers and typically want 8 to 10 of those to match. For cord blood transplants, only 4 to 6 matched markers are needed. Siblings have the best chance of being a full match, but unrelated donors found through registries can work when family matches aren’t available. A newer approach called haploidentical transplant allows a half-matched family member (a parent, child, or sibling) to serve as the donor, broadening the pool considerably.
Pre-Transplant Evaluation
Before you’re cleared for transplant, you’ll go through a series of tests to confirm your organs can withstand the procedure. These typically include heart and lung exams, kidney and liver function tests, blood and tissue typing, screening for infections like HIV and hepatitis, and age-appropriate cancer screenings such as mammograms or colonoscopies. The transplant team uses these results to determine whether the procedure is safe for you and to establish baseline measurements they’ll compare against during recovery.
The Conditioning Phase
Conditioning is the intensive treatment you receive in the days before transplant, and it’s often the hardest part of the process physically. High-dose chemotherapy, sometimes combined with total body irradiation, serves two purposes: it destroys the diseased cells in your marrow, and in allogeneic transplants, it suppresses your immune system enough that your body won’t reject the incoming donor cells.
The intensity of conditioning varies. Full-intensity (myeloablative) regimens completely wipe out your existing marrow. Reduced-intensity conditioning, sometimes called a “mini transplant,” uses lower doses that still suppress the immune system but rely more on the donor cells themselves to gradually replace diseased marrow. This approach has been a significant development because it extended transplant eligibility to adults up to age 75, opening treatment to patients who previously would have been considered too old or too frail for the procedure.
Conditioning typically lasts about a week. Side effects during this phase can include nausea, fatigue, mouth sores, and hair loss. Your blood counts will drop dramatically, leaving you highly vulnerable to infections.
The Transplant Day
The transplant itself is surprisingly undramatic compared to what comes before and after it. On what’s called “Day 0,” the stem cells are infused through a central venous catheter, a flexible tube that was placed in a large vein in your chest before conditioning began. The process looks and feels similar to receiving a blood transfusion. It takes anywhere from 1 to 5 hours depending on the volume of cells. You’ll be awake for the entire thing. Some patients experience mild reactions like chills, flushing, or a funny taste in the mouth (from the preservative used to store the cells), but serious complications during the infusion are uncommon.
Engraftment: Waiting for the Cells to Take Hold
After infusion, the transplanted stem cells travel through your bloodstream and settle into the cavities of your bones, where they begin producing new blood cells. This process is called engraftment, and it’s the critical milestone of the entire transplant. Until it happens, you have virtually no functioning immune system.
Engraftment typically occurs within two to four weeks. Doctors track it by monitoring your daily blood counts, watching for the first sustained rise in white blood cells, particularly a type called neutrophils. They also run specialized tests to measure “chimerism,” the ratio of donor cells to your own cells in the bloodstream. Full chimerism, meaning 100% donor cells, is the goal in allogeneic transplants. Mixed chimerism, where both donor and recipient cells coexist, may be acceptable in some cases but can also signal that the graft is weakening or that disease is returning.
The median hospital stay for an allogeneic transplant is about 25 days, based on data from over 63,000 inpatient transplants. Some patients stay longer depending on complications, infection risk, or how quickly their counts recover.
Graft-Versus-Host Disease
The most significant complication unique to allogeneic transplants is graft-versus-host disease (GVHD), where the donor’s immune cells recognize your tissues as foreign and attack them. It comes in two forms.
Acute GVHD usually develops within the first 100 days and most commonly targets the skin (rashes), the digestive tract (nausea, diarrhea, abdominal pain), and the liver. Chronic GVHD can appear months or even years later and affects a wider range of organs, including the skin, liver, gut, lungs, eyes, and joints. It can resemble autoimmune conditions, with symptoms like dry eyes, tight skin, or shortness of breath. Patients who receive peripheral blood stem cells rather than bone marrow have notably higher rates of chronic GVHD.
Ironically, a mild degree of graft-versus-host activity can be beneficial. The same donor immune cells that attack healthy tissue also attack any remaining cancer cells, a phenomenon called graft-versus-tumor effect. Managing GVHD often involves balancing the desire to suppress the harmful immune response without eliminating this anticancer benefit.
Recovery After Discharge
Leaving the hospital doesn’t mean recovery is over. For the first several months, you’ll have frequent outpatient visits for blood work, medication adjustments, and infection monitoring. Your immune system remains compromised for six months to a year or longer, meaning you’ll need to take precautions against infection: avoiding crowds, practicing careful hygiene, and in many cases receiving vaccinations again from scratch, since the transplant effectively resets your immune memory.
Most patients experience significant fatigue that gradually improves over months. Returning to work or normal activities typically takes 6 to 12 months, though this varies widely based on the type of transplant, the conditioning intensity, and whether complications like GVHD develop. Nutritional support, physical rehabilitation, and psychological care are all part of the recovery process, since the physical and emotional toll of transplant is substantial even when things go well.